Objective The 1980 American College of Rheumatology (ACR) classification criteria for
systemic sclerosis (SSc) lack sensitivity for early SSc and limited cutaneous SSc. The present …

Background We conducted a double-blind, randomized, placebo-controlled trial to determine
the effects of oral cyclophosphamide on lung function and health-related symptoms in …

Background 12 months of oral cyclophosphamide has been shown to alter the progression
of scleroderma-related interstitial lung disease when compared with placebo. However, …

Objective. The 1980 American College of Rheuma-tology (ACR) classification criteria for
systemic sclerosis (SSc) lack sensitivity for early SSc and limited cutaneous SSc. The present …

Rationale: The Scleroderma Lung Study enrolled 158 patients with scleroderma-related
interstitial lung disease in a placebo-controlled trial of oral cyclophosphamide (CYC). Although …

Objective: To evaluate the efficacy and safety of iloprost, a prostacyclin analog, administered
intravenously in patients with Raynaud phenomenon secondary to systemic sclerosis. …

The modified Rodnan skin score (mRSS) is a measure of skin thickness and is used as a
primary or secondary outcome measure in clinical trials of systemic sclerosis (scleroderma). …

… Address reprint requests to Philip J. Clements, MD, University of California, Los Angeles,
School of Medicine, Department of Medicine/Rheumatology, 32-59 Rehabilitation Center, Box …

Objective To study the clinical implications of a skin thickness score ≥20 at first visit and of
softening of sclerodermatous skin in a cohort of systemic sclerosis (SSc) patients with diffuse …

Thirty‐seven patients with psoriatic arthritis were entered into a 12‐week prospective, controlled,
double‐blind multicenter trial comparing placebo and oral pulse methotrexate therapy. …